Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 6, 2022; 10(19): 6555-6562
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6555
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6555
Figure 1 The progression-free survival of the 7 patients.
PFS: progression-free survival.
Figure 2 The overall survival of the 7 patients.
Figure 3 Treatment response of each patient and the duration of response after treatment with sintilimab and chidamide.
Figure 4 The positron emission tomography–computed tomography scans before and during the combined treatment of the patient 3.
- Citation: Hao YY, Chen PP, Yuan XG, Zhao AQ, Liang Y, Liu H, Qian WB. Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. World J Clin Cases 2022; 10(19): 6555-6562
- URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6555.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6555